Celcuity (NASDAQ:CELC) Director Sells $317,070.00 in Stock

Celcuity, Inc. (NASDAQ:CELC) Director Richard Buller sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $105.69, for a total transaction of $317,070.00. Following the transaction, the director directly owned 6,760 shares in the company, valued at approximately $714,464.40. This trade represents a 30.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

Celcuity Stock Down 1.3%

Shares of CELC traded down $1.32 during mid-day trading on Tuesday, hitting $102.72. The company’s stock had a trading volume of 929,850 shares, compared to its average volume of 745,203. The firm has a market capitalization of $4.75 billion, a price-to-earnings ratio of -27.99 and a beta of 0.21. The company’s 50-day moving average is $75.77 and its 200-day moving average is $47.08. The company has a current ratio of 12.26, a quick ratio of 12.26 and a debt-to-equity ratio of 2.74. Celcuity, Inc. has a 52-week low of $7.57 and a 52-week high of $108.91.

Celcuity (NASDAQ:CELC) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.92) EPS for the quarter, beating the consensus estimate of ($1.05) by $0.13. On average, equities research analysts forecast that Celcuity, Inc. will post -2.62 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. Needham & Company LLC set a $95.00 price objective on shares of Celcuity in a research note on Monday, October 20th. Wolfe Research began coverage on shares of Celcuity in a research note on Tuesday, November 18th. They issued an “outperform” rating and a $110.00 price target on the stock. Craig Hallum boosted their price target on Celcuity from $96.00 to $108.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Wall Street Zen lowered shares of Celcuity from a “hold” rating to a “sell” rating in a research note on Sunday, October 26th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Celcuity in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Celcuity has a consensus rating of “Moderate Buy” and a consensus price target of $102.29.

Institutional Trading of Celcuity

Several institutional investors and hedge funds have recently bought and sold shares of CELC. Nuveen LLC acquired a new position in shares of Celcuity in the first quarter valued at approximately $704,000. Wellington Management Group LLP lifted its stake in Celcuity by 35.1% in the 1st quarter. Wellington Management Group LLP now owns 84,825 shares of the company’s stock valued at $858,000 after buying an additional 22,049 shares in the last quarter. EntryPoint Capital LLC boosted its stake in shares of Celcuity by 18.4% during the first quarter. EntryPoint Capital LLC now owns 24,687 shares of the company’s stock valued at $250,000 after acquiring an additional 3,840 shares during the last quarter. Trexquant Investment LP grew its holdings in shares of Celcuity by 131.3% during the first quarter. Trexquant Investment LP now owns 26,920 shares of the company’s stock worth $272,000 after buying an additional 15,280 shares in the last quarter. Finally, Tema Etfs LLC purchased a new stake in Celcuity in the 1st quarter worth approximately $158,000. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.